Belite Bio Engages in Virtual Conference on Ophthalmology Progress

Belite Bio's Involvement in the H.C. Wainwright Conference

Belite Bio, Inc., a leading clinical-stage drug development company focused on the advancement of groundbreaking therapeutics for degenerative retinal diseases, is gearing up for a significant presence at the H.C. Wainwright Annual Ophthalmology Virtual Conference. This event is set to unfold on August 13, providing an essential platform for discussions on pivotal advancements in therapeutic strategies for retinal conditions.

Event Highlights

The executive management team at Belite Bio will partake in a comprehensive corporate presentation, alongside a panel discussion specifically centered on pivotal-stage assets for retinal disorders. Attendees can look forward to the following schedule:

• 7:00 am ET - On-demand corporate presentation

• 11:00 am ET - Panel discussion on 'Pivotal-Stage Assets for Retinal Disorders'

Webcast Details

For those interested, a webcast of the presentations will be accessible under the "Events" tab within the investor relations section of Belite Bio's official website. The company has ensured that replays of these sessions will be available for a duration of 90 days following the events, allowing missed attendees to catch up on the latest insights and developments.

About Belite Bio and Its Drug Development Focus

Belite Bio is at the forefront of addressing unmet medical needs associated with degenerative retinal conditions, prominently Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) linked with advanced dry age-related macular degeneration (AMD). Its lead candidate, Tinlarebant, is an innovative oral therapy designed to mitigate toxic accumulation within the eye. Currently, this candidate is being assessed in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) targeting adolescent STGD1 participants, along with a Phase 3 study (PHOENIX) focused on GA subjects.

Recent Developments and Research

Belite Bio has been ambitiously striving to enhance treatment options in ophthalmology. The research driving its clinical studies positions the company not only as a contributor to medical advancements but also as a beacon of hope for patients battling degenerative retinal diseases. The organization actively engages in clinical trials to evaluate the safety and efficacy of its treatments. Recently, it has expanded its research initiatives, seeking partnerships and collaborations with other entities to expedite the development of its therapeutics.

Connect with Belite Bio

Belite Bio encourages individuals to follow their journey through various social media platforms, including Instagram, LinkedIn, and Facebook. Those wanting to learn more about their efforts and advancements are invited to visit their website for ongoing updates and resources.

Media and Investor Relations Contact

For inquiries relating to media or investor relations, individuals can reach out to:

Jennifer Wu
Email: ir@belitebio.com

Julie Fallon
Email: belite@argotpartners.com

Frequently Asked Questions

What is Belite Bio's focus in drug development?

Belite Bio is focused on advancing therapeutics for degenerative retinal diseases, particularly STGD1 and GA associated with AMD.

When will the H.C. Wainwright Annual Ophthalmology Virtual Conference take place?

The conference is scheduled for August 13, featuring a corporate presentation and panel discussion.

How can the public access the conference presentations?

Presentations can be accessed via the "Events" tab on the investor relations section of Belite Bio's website, with replays available for 90 days post-event.

What is Tinlarebant?

Tinlarebant is Belite Bio's lead candidate for treating degenerative retinal conditions, showing promise in Phase 3 and Phase 2/3 clinical trials.

How can investors get in touch with Belite Bio?

Investors can contact Jennifer Wu at ir@belitebio.com for inquiries regarding investor relations.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.